EN001 (mesenchymal stem cell therapy)
An investigational treatment for Charcot-Marie-Tooth Disease.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify EN001 (mesenchymal stem cell therapy) wherever you encounter it, plus the key facts at a glance.
- Generic name
- EN001 (mesenchymal stem cell therapy)
- Development codes
- EN001, EN-001
- Drug class
- Mesenchymal stem cell therapy (intravenous)
- Manufacturer
- ENCell (Republic of Korea)
- How it's taken
- Given as an intravenous (IV) infusion in a clinic or infusion center.
An investigational mesenchymal stem cell therapy in development by ENCell (a Korean biotech) for CMT1A, made from donor umbilical cord tissue (Wharton's jelly).
- A Phase 1 trial in 9 adults with genetically confirmed CMT1A finished in December 2022, and results presented in 2024 showed the therapy was well tolerated, with improvements in CMT Neuropathy Score, walking tests, and nerve conduction.
- A Phase 1b/2a trial is enrolling in South Korea.
- The FDA granted EN001 Orphan Drug Designation for CMT in March 2025.
We'll email you when the FDA acts on EN001 (mesenchymal stem cell therapy) and when new trials for Charcot-Marie-Tooth Disease open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where EN001 (mesenchymal stem cell therapy) fits
Investigational, not approved.
- A cell therapy for CMT1A, different in approach from gene therapies and PMP22-modulating drugs because it works through MSC paracrine effects rather than addressing the genetic defect.
- Only relevant for patients with confirmed CMT1A (PMP22 duplication on genetic testing).
How EN001 (mesenchymal stem cell therapy) works
Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be grown in laboratories from sources like bone marrow or umbilical cord. They have been studied in many different diseases for their ability to send anti-inflammatory and tissue-supportive signals (so-called paracrine effects) to nearby cells. They generally do not work by transforming into the damaged cell type and replacing it.
In CMT1A, the peripheral nerves and the Schwann cells that produce myelin around them are progressively damaged because of an extra copy of the PMP22 gene. EN001 is a specific MSC-based therapy that ENCell developed in the lab and tested in animal models of CMT1A, where it was shown to help support myelin and improve some measures of nerve function.
In the Phase 1 trial, EN001 was given as a single intravenous infusion at one of two doses. Patients showed improvements in standard CMT measures (CMT Neuropathy Score, 10-Meter Walking Test, nerve conduction) at 16 weeks, with the high-dose group benefiting more. Whether these improvements are durable and whether they can be sustained with repeat dosing are questions the Phase 1b/2a trial is designed to answer.
Clinical trial results
Phase 1 (NCT05333406) enrolled 9 adults with genetically confirmed CMT1A at Samsung Medical Center in Seoul, assigned without randomization to a single IV infusion of EN001 at 0.5 million or 2.5 million cells per kilogram. Results were presented at the Peripheral Nerve Society annual meeting in Montreal in 2024.
The CMT Neuropathy Score version 2 dropped by an average of 2.89 points across all patients at 16 weeks (3.5 points in the high-dose group), with improvements also reported on the 10-Meter Walking Test, the Functional Disability Scale, and nerve conduction studies. The Phase 1b/2a trial (NCT06328712) began in May 2024 and plans about 27 patients in total, including a 21-patient Phase 2a part that compares 2 doses with placebo on the CMT Neuropathy Score at 24 weeks.
ClinicalTrials.gov lists 3 recruiting sites, all in South Korea, and an estimated completion at the end of 2026.
Main registered trial: NCT06328712 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.
Side effects and safety
In the Phase 1 trial in 9 patients, EN001 was well tolerated, with no dose-limiting or serious adverse events and no infusion-related reactions. Mesenchymal stem cell therapies as a class are generally considered low-risk for systemic toxicity, though longer-term and larger-scale data are still being collected for EN001 specifically.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking EN001 (mesenchymal stem cell therapy)
Given as an intravenous (IV) infusion in a clinic or infusion center. Phase 1 used a single infusion at one of two doses, 0.5 million or 2.5 million cells per kilogram of body weight. In the Phase 1b/2a trial, each participant gets 2 infusions 4 weeks apart at a low or high dose, or placebo in the Phase 2a part.
Development history
ENCell developed EN001 specifically for CMT1A, building on preclinical work showing mesenchymal stem cells could support nerve and Schwann cell function in animal models. After completing Phase 1 in Korea, ENCell received Orphan Drug Designation from the U.S. FDA for EN001 in CMT in March 2025. The Phase 1b/2a trial is enrolling under approval from the Korea Food and Drug Administration.
Explore Charcot-Marie-Tooth Disease trials
Other Charcot-Marie-Tooth Disease treatments
Common questions about EN001 (mesenchymal stem cell therapy)
▸What is EN001 (mesenchymal stem cell therapy)?
An investigational mesenchymal stem cell therapy in development by ENCell (a Korean biotech) for CMT1A, made from donor umbilical cord tissue (Wharton's jelly). A Phase 1 trial in 9 adults with genetically confirmed CMT1A finished in December 2022, and results presented in 2024 showed the therapy was well tolerated, with improvements in CMT Neuropathy Score, walking tests, and nerve conduction. A Phase 1b/2a trial is enrolling in South Korea. The FDA granted EN001 Orphan Drug Designation for CMT in March 2025.
▸How does EN001 (mesenchymal stem cell therapy) work?
Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be grown in laboratories from sources like bone marrow or umbilical cord. They have been studied in many different diseases for their ability to send anti-inflammatory and tissue-supportive signals (so-called paracrine effects) to nearby cells. They generally do not work by transforming into the damaged cell type and replacing it.
In CMT1A, the peripheral nerves and the Schwann cells that produce myelin around them are progressively damaged because of an extra copy of the PMP22 gene. EN001 is a specific MSC-based therapy that ENCell developed in the lab and tested in animal models of CMT1A, where it was shown to help support myelin and improve some measures of nerve function.
In the Phase 1 trial, EN001 was given as a single intravenous infusion at one of two doses. Patients showed improvements in standard CMT measures (CMT Neuropathy Score, 10-Meter Walking Test, nerve conduction) at 16 weeks, with the high-dose group benefiting more. Whether these improvements are durable and whether they can be sustained with repeat dosing are questions the Phase 1b/2a trial is designed to answer.
▸What are the side effects of EN001 (mesenchymal stem cell therapy)?
In the Phase 1 trial in 9 patients, EN001 was well tolerated, with no dose-limiting or serious adverse events and no infusion-related reactions. Mesenchymal stem cell therapies as a class are generally considered low-risk for systemic toxicity, though longer-term and larger-scale data are still being collected for EN001 specifically.
▸How is EN001 (mesenchymal stem cell therapy) taken?
Given as an intravenous (IV) infusion in a clinic or infusion center. Phase 1 used a single infusion at one of two doses, 0.5 million or 2.5 million cells per kilogram of body weight. In the Phase 1b/2a trial, each participant gets 2 infusions 4 weeks apart at a low or high dose, or placebo in the Phase 2a part.
▸Is EN001 (mesenchymal stem cell therapy) FDA approved?
EN001 (mesenchymal stem cell therapy) is currently in phase 2 clinical trials for Charcot-Marie-Tooth Disease. It has not yet received FDA approval.
▸Is EN001 FDA approved?
No. EN001 is not FDA-approved. It is an investigational mesenchymal stem cell therapy for CMT1A developed by ENCell, and it is currently in a Phase 1b/2a trial that began in May 2024. The FDA granted EN001 Orphan Drug Designation for CMT in March 2025, which is a development incentive and not the same as approval. [1][3]
▸What did the EN001 Phase 1 trial show?
The Phase 1 trial enrolled 9 adults with genetically confirmed CMT1A who received a single IV infusion of EN001 at either 0.5 million or 2.5 million cells per kilogram of body weight. At 16 weeks, the CMT Neuropathy Score version 2 dropped by an average of 2.89 points across all patients and 3.5 points in the high-dose group, with improvements also reported on the 10-Meter Walking Test, the Functional Disability Scale, and nerve conduction studies. Results were presented at the Peripheral Nerve Society annual meeting in Montreal in 2024. [2]
▸How is EN001 given?
EN001 is given as an intravenous infusion in a clinic or infusion center. In the Phase 1 trial, patients received a single infusion at one of two doses, 0.5 million or 2.5 million cells per kilogram of body weight. In the Phase 1b/2a trial (NCT06328712), participants get 2 infusions 4 weeks apart, and whether benefits last or can be sustained with repeat dosing is one of the questions that trial is designed to answer. [5][4]
▸What are the side effects of EN001?
In the Phase 1 trial of 9 patients, EN001 was well tolerated, with no dose-limiting or serious adverse events and no infusion-related reactions. Mesenchymal stem cell therapies as a class are generally considered low risk for systemic toxicity, but longer-term and larger-scale safety data for EN001 specifically are still being collected. [2]
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- ENCell (Business Wire) · March 6, 2025. ENCell's EN001 Receives Orphan Drug Designation from the U.S. FDA for Charcot-Marie-Tooth Disease. https://www.businesswire.com/news/home/20250306675394/en/ENCells-EN001-Receives-Orphan-Drug-Designation-from-the-U.S.-FDA-for-Charcot-Marie-Tooth-Disease
- ENCell (Business Wire) · June 24, 2024. ENCell Presents Phase 1 Clinical Trial Results of Mesenchymal Stem Cell Therapy EN001 for Charcot-Marie-Tooth Disease at PNS Conference. https://www.businesswire.com/news/home/20240624485930/en/ENCell-Presents-the-Phase-1-Clinical-Trial-Results-of-their-Mesenchymal-Stem-Cell-Therapy-EN001-for-Charcot-Marie-Tooth-Disease-at-the-PNS-conference
- Charcot-Marie-Tooth Association. ENCell Announces Phase 1b/2a Stem Cell Trial for CMT1A. https://cmtausa.org/simply-cmt/encell-phase-1b-2a-trial/
- ClinicalTrials.gov. A Phase 1b/2a Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients With CMT1A. https://clinicaltrials.gov/study/NCT06328712
- ClinicalTrials.gov. Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A. https://clinicaltrials.gov/study/NCT05333406